Skip to main content
ICPE 2023 Main banner
Final Program


ICPE 2023 Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Video

Effectiveness of Antidiabetic Treatments

Friday, August 25, 2023
1:30 PM – 3:00 PM ADT
Location:MR109

    Co-Moderator(s)

  • Cynthia Girman, DrPH FISPE

    Founder and President
    CERobs Consulting, LLC
    Department of Epidemiology, Gillings Global School of Public Health, University of North Carolina, Chapel Hill, NC USA
    Wrightsville Beach, United States

  • Edward Chia-Cheng Lai, PhD, FISPE (he/him/his)

    Associate Professor
    Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan
    National Cheng Kung University
    Tainan City, Taiwan (Republic of China)

Presentations:

  • 1:30 PM – 1:45 PM ADT
    Heterogenous effects of sodium-glucose cotransporter-2 inhibitors on nephrolithiasis in older adults with type 2 diabetes

    Presenting Author: Yujia Li, MS – Department of Pharmaceutical Outcomes & Policy, University of Florida College of Pharmacy

  • 1:45 PM – 2:00 PM ADT
    Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer Among Patients with Type 2 Diabetes: Population-Based Cohort Study

    Presenting Author: Richeek Pradhan, MD, MS, PhD (he/him/his) – Harvard Medical School and Brigham and Women's Hospital

  • 2:00 PM – 2:15 PM ADT
    Healthcare utilization and cost associated with Empagliflozin in Older Adults with Type 2 Diabetes: Results from the EMPRISE study

    Presenting Author: Phyo Than T. Htoo, MD, PhD – Division of Pharmacoepidemiology, Dept. of Medicine, Brigham & Women’s Hospital, Harvard Medical School

  • 2:15 PM – 2:30 PM ADT
    SGLT2 Inhibitors Associated with Decreased Risk of Nephrolithiasis Compared to GLP-1 Receptor Agonists: An Active Comparator, New User Cohort Study

    Presenting Author: Adrian Martinez-De la Torre, PhD – Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland

  • 2:30 PM – 2:45 PM ADT
    Sodium-Glucose Cotransporter-2 Inhibitors, and Glucagon-Like Peptide-1 Receptor Agonists, and the Risk of Macrovascular, and Microvascular Complications Among Patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

    Presenting Author: Sungho Bea, PharmD – School of Pharmacy, Sungkyunkwan University, Suwon, South Korea

  • 2:45 PM – 3:00 PM ADT
    Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study

    Presenting Author: Helen Tesfaye, PharmD, MSc – Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA